JNJ-88998377

Unknown / undisclosed

Also known as JNJ-8377

Phase 1Mechanism not established

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1 (1)
B-Cell Non-Hodgkin Lymphoma
NCT06470438 · Janssen Research & Development, LLC
2024-05-28 – 2028-12-29 · Lymphoma, Non-Hodgkin, Refractory B-Cell NHL, Relapsed B-cell NHL
What this study did

Competitive landscape

This drug's own stage for B-Cell Non-Hodgkin Lymphoma: Phase 1. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
JNJ-88998377: this drugPhase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
PF-05280586ApprovedBiologic (subtype unspecified)CD20not yet gradedNo reviewed efficacy summary in this indication
OdronextamabPhase 3Multispecific antibodyCD20 x CD3not yet gradedNo reviewed efficacy summary in this indication
SurovatamigPhase 2Multispecific antibodyCD19 x CD3not yet gradedNo reviewed efficacy summary in this indication
AZD4512Phase 1/2Antibody–drug conjugateCD22not yet gradedNo reviewed efficacy summary in this indication
REGN5837Phase 1Multispecific antibodyCD22 x CD28not yet gradedNo reviewed efficacy summary in this indication
SHR-3079Phase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
Vispacabtagene RegedleucelDiscontinuedCell therapyCD19not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow JNJ-88998377 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
October 2027 (1)
Phase 1B-Cell Non-Hodgkin LymphomaActive not recruiting
Est. primary completion 2027-10-29 · NCT06470438 · CT.gov ↗
What to watch

See the full readout calendar ↗